Tango Therapeutics Cash Flow Statement
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.81+1.24 (+5.49%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tango Therapeutics free cash flow
In fiscal 2025, Tango Therapeutics generated -$138.9 million of operating cash flow and spent $1.0 million on capital expenditures. That left free cash flow of -$139.9 million, a free-cash-flow margin of -224.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Tango Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M | -51.97M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 2.28M | 2.50M | 2.42M | 1.61M | 897.00K | 718.00K |
| Stock-Based Compensation | 26.43M | 28.90M | 19.08M | 14.23M | 7.83M | 1.76M |
| Change in Working Capital | -64.97M | -30.78M | -33.46M | -17.82M | -13.97M | 118.17M |
| Operating Cash Flow | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M | 70.07M |
| Capital Expenditures | -1.05M | -754.00K | -1.53M | -7.69M | -1.84M | -1.11M |
| Investing Cash Flow | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M | -145.47M |
| Financing Cash Flow | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M | 80.88M |
| Net Change in Cash | 42.75M | 2.29M | 5.85M | -81.07M | 114.36M | 5.49M |
| Free Cash Flow | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M | 68.97M |
This table shows 6 annual periods of Tango Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TNGX's reporting calendar. What is a cash flow statement?